ARCUS BIOSCIENCES
Arcus Biosciences is an oncology-focused clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer. It aims to create new cancer therapeutics through the utilization of emerging insights in immunology. The company has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different in... dications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. Arcus was formed in 2015 in Hayward, California by Terry Rosen and Juan Jaen.
ARCUS BIOSCIENCES
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Hayward, California, United States
Country:
United States
Website Url:
http://www.arcusbio.com
Total Employee:
101+
Status:
Active
Contact:
+1 510-694-6200
Email Addresses:
[email protected]
Total Funding:
647.05 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Cogent Biosciences
Cogent Biosciences is a biopharmaceutical company that develops therapies for solid cancer tumors.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Gilead Sciences
Gilead Sciences investment in Post-IPO Equity - Arcus Biosciences
Gilead Sciences
Gilead Sciences investment in Post-IPO Equity - Arcus Biosciences
The Column Group
The Column Group investment in Series C - Arcus Biosciences
Biotechnology Value Fund
Biotechnology Value Fund investment in Series C - Arcus Biosciences
Decheng Capital
Decheng Capital investment in Series C - Arcus Biosciences
Droia Ventures
Droia Ventures investment in Series C - Arcus Biosciences
Aisling Capital
Aisling Capital investment in Series C - Arcus Biosciences
Taiho Ventures
Taiho Ventures investment in Series C - Arcus Biosciences
Celgene
Celgene investment in Series C - Arcus Biosciences
Leerink Partners
Leerink Partners investment in Series C - Arcus Biosciences
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-08 | Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer |
| 2020-10-01 | Arcus Biosciences names Jennifer Jarrett as new COO |
| 2020-07-07 | Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer |
Official Site Inspections
http://www.arcusbio.com Semrush global rank: 1.76 M Semrush visits lastest month: 13.27 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
